SUBSCRIBE TODAY!
Subscribing entitles a reader to complete stories on all topics released as they happen, special features, confidential documents and access to the complete, searchable story archive online back to 2004.
IP-Watch Briefs

Inside Views

Contribute your views! Submit an Inside Views idea to info [at] ip-watch [dot] ch.

We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

Call For Transparency In The Trans-Pacific Partnership Negotiation

In this post, three US law professors explain a recent call by over 30 legal scholars for the US Trade Representative to increase transparency for the Trans-Pacific Partnership Agreement intellectual property chapter, and their response to Ambassador Kirk’s response that he is “strongly offended” by the suggestion that the negotiation is not adequately transparent already.





Latest Comments
  • David, thank you for the note. It appears there is... »
  • The link to the US proposal seems to be broken, an... »

  • For IPW Subscribers
    A guide to Geneva-based public health and intellectual property organisations. Read More >

    Monthly Reporter

    The Intellectual Property Watch Monthly Reporter, published from 2004 to January 2011, is a 16-page monthly selection of the most important, updated stories and features, plus the People and News Briefs columns.

    The Intellectual Property Watch Monthly Reporter is available in an online archive on the IP-Watch website, available for IP-Watch Subscribers.

    Access the Monthly Reporter Archive >


    Submissions To US Unilateral IP Enforcement Process Highlight Piracy, Health, and ACTA

    Published on 5 March 2010 @ 5:11 pm

    By and , Intellectual Property Watch

    Submissions to the United States annual review of how well it says the rest of the world is protecting US intellectual property are being assessed this week, with marked changes from previous years.

    In a process typically dominated by industry groups and the occasional stakeholding nonprofit, 2010 submissions not only included far more public interest groups but also a significant number of submissions from private citizens – primarily commenting on the tangentially-related Anti-Counterfeiting Trade Agreement. This year is also notable as it is the first review process conducted after the new Obama administration has developed its trade agenda. The new trade agenda, released this week, might give some clues about the Obama administration’s thinking.

    Submissions from major industry groups discussed the interplay between IP and public health, and one particularly controversial copyright industry contribution called out governments on their procurement of open source software.

    Industry groups also cited typical targets of concern about piracy and counterfeiting and internet-based copyright infringement such as China and Russia. The International Intellectual Property Alliance said China had an inadequate enforcement system and that piracy of books, CDs, movies and software was “widespread” and that US businesses’ ability to conduct lawful business was limited. IIPA also cited Canada for not having updated its copyright law.

    Every year the Office of the US Trade Representative (USTR) identifies countries it says are failing to provide effective protection of US IP rights or denying fair and equitable market access to US persons relying on IP protection. This is under a provision of Section 182 of the Trade Act of 1974 (Trade Act), commonly referred to as “Special 301.”

    USTR has a “watch list” and a “priority watch list” to indicate trade partners that are allegedly not complying with international obligations for IP protection and market access. Placement on the list carries the (seldom-used) threat of removal of unilateral US trade benefits. USTR accepts comments from stakeholders on foreign country policies, acts or practices that might be identified as infringing US IP rights.

    Normally this means commentary comes from industry stakeholders, but this year marked a change as comments came also from nongovernmental organisations, governments, universities and hundreds of individual US citizens. There were hundreds of submissions to the process, available here.

    On 3 March, the USTR held its first-ever public hearing in the special 301 review process, with 25 government representatives, nonprofits, academics and industry groups scheduled to speak. The audio is available here; some foreign delegations based abroad were reportedly unable to speak as live streaming of the event was not allowed.

    Individuals Decry ACTA Secrecy; Researchers Applaud 301 Transparency

    While public interest groups have been campaigning against the secretive Anti-Counterfeiting Trade Agreement for two years, this may be the first time in which large numbers of private citizens have made a coordinated effort to do so. Part of this seems to have sprung from a campaign by advocacy group Public Knowledge, which posted information on its website calling for a “balanced copyright regime” and encouraging citizens to contribute to the 301 process with an easy-to-use web form. One of the first comments on the Public Knowledge campaign page quotes civil liberties group Electronic Frontier Foundation’s criticism of the ACTA.

    All ACTA commentators – of which there were hundreds – decried ACTA’s secrecy, calling it inappropriate not to involve consumers and citizens in a treaty that will personally affect them; some added that needed secrecy is a sign of anti-consumerism. Several IP owners also wrote in to express their particular dissatisfaction.

    Writer and musician John Young said, “I believe the regime of ‘protections’ of creative work as generally advocated by copyright institutions in the US are far more focused on protecting the profits of licensing corporations than protecting the vigorous exchange and resynthesis of ideas necessary for my trade to function properly,” he wrote, and appealed to the USTR not to “make the mistake of exporting the broken state of copyright from the US to foreign countries.”

    photo by <a href="http://www.adavies.org">Andrew Davies</a>

    photo by Andrew Davies

    Shawn Stricker, a film, music and software creator, said the secrecy is a “fertile breeding ground for corruption” and that “laws that restrict the free exchange of ideas, however seemingly well intentioned, are the tools of tyranny, and will be misused by profit-seeking corporations and by governments seeking to control and restrict their citizens.” And photographer Andrew Davies said as a creative professional and an IP owner he was “alarmed by the trend of locking up content,” and demonstrated his commitment to non-restrictive licensing by submitting a digital photograph of a bucolic mountain scene to the USTR under a Creative Commons Attribution NonCommercial license. “Why? Because I can.”

    “Since the inauguration of the [World Trade Organization] in 1994, the USTR has operated in a position of ambiguous legality and soft power, able to threaten countries through Special 301 but mostly unable to implement unilateral sanctions for fear of generating an adverse WTO ruling,” said the Social Science Research Council. Over the years, factors such as the rising awareness of developing countries toward IP policy and enforcement have changed the conditions that formerly allowed “IP policy making to fly under the radar of most consumers and public interest groups,” they said. The Council pictured a “more transparent and participatory Special 301 process” as the “only viable way forward for all parties.”

    Foreign Governments Comment

    Most foreign government statements discussed improvements in national intellectual property systems, reiterated commitments to prevent piracy and to protect IP (and often emphasised enforcement measures taken as well as arrests and seizures made), and stated expectation that these efforts should improve their status on the Special 301 report. Comments came from a variety of places, including Costa Rica, Indonesia, Italy, Pakistan, Spain and Turkey, among others. Not many protested the US’s pressure related to their national IP protection.

    India’s submission, while on similar lines, defended its patent system as “fair and transparent,” said that patent applicants could appeal if they thought they had been rejected unfairly, and noted that it is “important to distinguish between legitimate generics and spurious or counterfeit drugs.”

    Thailand said it had “actively recruited participation of [the] US pharmaceutical industry” in order to “identify constructive ways and means to ensure continued supply and access to medicines,” and is creating a joint database with the US Food and Drug Administration on patented pharmaceuticals. The country has also pledged $700,000 to upgrade its patent system. Thailand has previously been put on the priority watch list in part due to compulsory licences issued on pharmaceutical products it deemed necessary to obtain more cheaply.

    A coalition of Thai civil society organisations submitted a comment saying most essential medicines in the country “are patented and their prices are very expensive” leaving little choice to use the compulsory licence flexibility but that this move was “heavily opposed” by the US government and “harshly retaliated” by the US pharmaceutical industry. The comment asked that Special 301 no longer be used to push policies stronger than the TRIPS agreement.

    Public Health and IP Draws Comment

    Issues of IP flexibilities and public health drew attention from groups on all sides of the table, and raised some questions about World Trade Organization rules on IP rights such as those allowing flexibilities to IP rights like compulsory licences for public health reasons.

    The Pharmaceutical Research and Manufacturers of America registered an objection to Thailand and protested several public health laws as potentially inhibiting future access to innovative drugs. These included a health law in Indonesia that sought to expand compulsory licences or other government uses of patented medicines, price controls on branded generics, private sector financing to the public sector; a cheaper medicines act in the Philippines that required price-cutting on five drugs; and regulations in several European countries capping pharmaceutical prices.

    The Biotechnology Industry Organization similarly criticised Thailand on “egregious and onerous policies relating to compulsory licensing,” as well as Chile and Indonesia on data protection measures related to biotechnology, China on the trafficking of counterfeit drugs, India on what BIO said were too-narrow patentability standards.

    Oxfam voiced concerns about the Special 301 report being used to sanction countries which had employed legitimate measures to protect public health, and has encouraged an inappropriately high level of IP protection in low and middle-income countries, limiting access to medicine. According to its submission, Oxfam called for the USTR to “take a fresh look at its approach to intellectual property provisions.”

    A joint submission of several major global health organisations coordinated by Sean Flynn of the American University College of Law (Washington, DC) called on USTR to stop using the Special 301 report to promote so-called “TRIPS-plus restrictions on access to medicines,” which the groups said violates the Doha Declaration on IP flexibilities and public health. “TRIPS-plus” refers to laws that go beyond obligations negotiated under the World Trade Organization Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, including a 2001 declaration in Doha that clarifying that countries have a right to use built-in health-related flexibility in TRIPS.

    Médecins sans Frontières (Doctors without Borders) said TRIPS gives countries the right to define their own patentability criteria and the right to issue compulsory licences, and called on the USTR to stop using the Special 301 report to pressure developing countries to implement stronger domestic IP laws than are required by international law.

    Public Citizen echoed the call for USTR to respect IP flexibilities for public health, in particular saying Ecuador should not be sanctioned for issuing compulsory licences on needed medicines (including indirectly “through imprecise references to alleged IPR-protection failings.”

    According to Knowledge Ecology International, USTR is pushing for TRIPS-plus provisions in developing countries by censuring countries which do not grant exclusive rights for the registration of pharmaceutical test data. The unavailability of those data is preventing generic manufacturers “from relying on the safety and efficacy data of the original clinical trials to register their products,” it said.

    Software, Seeds and Cigarettes

    Other commentary came in from a variety of sectors.

    IIPA, which collectively represents the major US copyright industry groups, drew commentary from internet rights groups and open source software proponents by saying that government procurement policies encouraging or mandating the use of open source software were akin to piracy. The IIPA suggested Brazil, India, Indonesia, the Philippines, Thailand and Vietnam be put on USTR watch lists for policies favouring open source software, saying it limited the ability of proprietary software to compete.

    Philip Morris said the increasing number of countries proposing to adopt plain packaging for cigarettes, or having heath warnings covering more than 50 percent of cigarette packaging is worrisome, as it might infringe trademark rights, and encourage “illicit trade in tobacco products.” The cigarette maker called for their IP rights to be protected and enforced in a number of countries, arguing that “these initiatives, which are not based on any solid scientific evidence that they contribute to legitimate public health objectives, would effectively constitute an expropriation of some of the world’s most valuable trademarks without the payment of adequate compensation to manufacturers.”

    The Free Software Foundation called for an end to digital rights management software, which they said prevents users from freely enjoying their purchases and are almost always incompatible with free software.

    The National Association of Manufacturers (NAM) said that IP rights were wrongly considered to be mainly the concern of sectors such as pharmaceuticals, software, and entertainment. International counterfeiting and piracy is a “mainstream and Main Street issue for US manufacturers,” they said. The specific focus of NAM in 2010 is “four Cs”: counterfeiting, customs, cooperation internationally and China.

    Agricultural technology company Monsanto complained about patent backlogs in Argentina and Brazil, which it said delays their ability to enter the market and enforce rights on their products, and about government procurement that favours locally owned or registered IP in China. The European Union’s recent trend to “unduly broaden breeder’s exemptions” will undermine IP rights on plants, Monsanto said. Breeders exemptions are intended to protect plant varieties while not restricting follow-on innovation by people other than the original rights holder.

    USTR’s final report is due in April.

    Catherine Saez may be reached at csaez@ip-watch.ch.

    Kaitlin Mara may be reached at kmara@ip-watch.ch.

     

    Comments

    1. James Love says:

      A lot of the problem with the Special 301 process historically is the mixing of enforcement and norm-setting. In some cases, lower standards of protection may be more appropriate, if you expect high levels of enforcement. Also, super high IPR norms are not really in the U.S. interest, as much of our valuable services sector today depend upon fairly robust exceptions, open standards, and access knowledge. The Special 301 process has sort of evolved into a fairly mindless embrace of selective industry hardline talking points on IPR norms. If the Obama administration intends to change this, they will have to find some people for the subcommittee who have more sophistication about these issues than the people who showed up this week.


    Leave a Reply

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website. By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

    By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

    2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

    3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

    4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

    5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

    6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

    7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

    8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

    9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.